Huma Therapeutics Limited has acquired Alcedis GmbH, in a move that will create new and advanced digital solutions across all phases of clinical trials.
Following the acquisition, leading global digital health company Huma will form an advanced clinical trials division offering digital solutions across the entire development pipeline.
Huma’s digital expertise will integrate with Alcedis’ clinical and operational know-how and support the seamless integration of digital technology into clinical trials.
This will help accelerate patient recruitment and speed up the development of new therapies through end-to-end digital-first research and care.
Combined, the two companies have undertaken nearly a thousand studies across a wide range of therapeutic areas, in over 60 countries involving more than 650,000 participants. Study areas include rare diseases, oncology, metabolic diseases, cardiovascular, neurodegenerative, dermatology and more.
Dan Vahdat, CEO and founder of Huma, said: “Huma has been a leader in digital-first care and research, partnering with health systems and pharma companies and now with this acquisition we’re set to redefine the clinical trials sector.”
Improved clinical know-how built into digital health technologies has been a challenge for the field set by sponsors such as pharma companies and CROs.
The acquisition and launch of a new clinical division will propel technology integration across all phases of clinical trials from early stage through to Phase IV hybrid and fully decentralised trials.
Hanno Härtlein, managing director at Alcedis, said: “We are excited to be joining the Huma family, bringing our clinical trials expertise and capabilities to combine with those of Huma’s award-winning technology-platform.
“Together, we will offer substantially greater benefit to pharmaceutical, medtech, clinical research organisation, and academic partners for their research projects.”
The new combined company will offer a one-stop shop for remote access, data, logistics and execution. Advanced digital technology will help to shape this new clinical research ecosystem.
Financial terms of the acquisition have not been disclosed.
A year ago, Huma acquired iPLATO Healthcare to enhance remote patient monitoring.